Psychiatric Drugs
Note:  This Page is Substantially Out of Date

• Neuroleptic Awareness
• Symbyax (Zyprexa and Prozac combination) Patient Information Sheet that will probably be watered down or even eliminated.
• Stimulants and ADHD: FDA March, 2006 Hearings
• Dear Health Care Professional" Alert on Haldol, September 17, 2007.  Information for Healthcare Professionals Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate) FDA ALERT [9/2007]: This Alert highlights revisions to the labeling for haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). The updated labeling includes WARNINGS stating that Torsades de Pointes and QT prolongation have been observed in patients receiving haloperidol, especially when the drug is administered intravenously or in higher doses than recommended. Haloperidol is not approved for intravenous use
• FDA June 18, 2007, Recommendation of Approvable Action for risperidone (Risperdal®) for the Treatment of Schizophrenia and Bipolar I Disorder in Pediatric Patients (response to PWR).
  • Clinical Pharmacology/Biopharmaceutics Review: BPCA Summary Review, dated December 22,1006.
• FDA Issues Warning Letter to Cephalon regarding false and misleading promotion of Provigil (modanfil), February 27, 2007..
• Making Sense of Coming off Psychiatric Drugs from Mind in the UK.
• January 20, 2007, study on the spermicidal and anti-STI properties of antidepressants. In vitro tests found that all of the SSRIs are spermicidal, and four types also kill the bacteria that cause Trichomonas, the world's most common sexually transmitted disease.
• November 16, 2006, FDA Warning Letter to Astra-Zeneca for misleading Seroquel (quetiapine) marketing materials for minimizing the risk of hyperglycemia and diabetes mellitus and failing to communicate important information regarding neuroleptic malignant syndrome, tardive dyskinesia and the bolded cataracts precaution.
• SSRI Antidepressants and Violence.
• August 4, 2006, "Dear Health Care Professional" letter from GlaxoSmithKline warning of a host of problems created by Dexedrine, including heart attacks and psychotic reactions.  GSK promotes Dexedrine for use by kids diagnosed with "Attention Deficit Hyperactivity Disorder"
• BBC July 1, 2006, article on Clozapine, Schizophrenia drug 'health risk'.

• Health Canada "Dear Health Care Letter" regarding the heart damaging characteristics of ADHD drugs, May 2006.

• Associated Press, February 10, 2006: FDA Panel recommends "Black Box" warning regarding lethal potential of ADHD Drugs (Ritalin, etc.).
• Anatomy of an Epidemic: Psychiatric Drugs and the Astonishing Rise of Mental Illness in America, by Robert Whitaker, Ethical Human Psychology and Psychiatry, Volume 7, Number I: 23-35 Spring 2005.
• Cytogenetic effects in children treated with methylphenidate, by Randa A. El-Zeina, Sherif Z. Abdel-Rahmanb, Matthew J. Hay, Mirtha S. Lopez, Melissa L. Bondy, Debra L. Morris, Marvin S. Legator in Cancer Letters 2 xx (2005) 1–8, documenting a 3, 4.3 and 2.4-fold increase in chromosome aberrations, sister chromatid exchanges and micronuclei frequencies in the pediatric use of Ritalin.
• June 1, 2005, Freedom of Information Act transmittal of Adverse Reactions to Olanzapine (Zyprexa).  (13 MB)
  • Detail  (19 MB) 
• FDA Issues Public Health Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in Elderly Patients, April 11, 2005.
  • Public Health Advisory
• Dr. Grace Jackson's June 6, 2004 Public Lecture, "What Doctors May Not Tell You About Psychiatric Drugs," to the UCE Centre for Community Mental Health, in Birmingham, England.
• Pfizer's August, 2004, "Dear Health Care Practitioner" letter on Geodon and increased risk of diabetes and related problems.
• GlaxoSmithKline Settles NY Fraud Suit, August 26, 2004.  See, Consent Decree (Settlement) and Press Release.
• Janssen, July 21, 2004 "Dear Health Care Provider" Letter for Risperidone (Risperdal) warning about the risk of diabetes.
  • April 19, 2004, FDA Warning Letter to Janssen about its previous Dear Health Care Provider being "false or misleading," which resulted in the July 21, 2004  letter.
• Astra Zeneca April 22, 2004, "Dear Health Care Provider" updated letter on Serequel after the FDA said its earlier letter was improper.
• Bristol Squibb March 25, 2004, Myers "Dear Dr. Health Care Practitioner" letter for Abilify (aripiprazole).
• Eli Lilly March 1, 2004, "Dear Health Care Provider Letter" for Olanzapine (Zyprexa) warning about the risk of diabetes.
• Benzodiazepines: How They Work and How to Withdraw by Professor C H Ashton DM, FRCP
• Sen. Grassley's March 25, 2004,  Letter to FDA opening investigation on SSRI anti-depressants.
• Allen Jones' Full Whistle-Blower Report on Drug Company influence on states' drug purchases.
  • NY Times 2/1/2004,  article, Making Drugs, Shaping the Rules about this.
• Paxil Litigation Update from the Baum Hedland law firm.
• Adverse Drug Effect Websites
• Off Label Prescribing Stories about Prozac leading to Milton Cole's Death
• ASPIRE's Research Compendium focused on SSRIs (Paxil, Prozac, Zoloft, etc.)
• Drug Company's Promotion of Unauthorized Use of Neurontin Exposed.  New York Times
• Drug giant accused of false claims (for Neurontin): Whistleblower alleges illegal encouragement of off-label use MSNBC
• Withdrawal from paroxetine (Paxil) can be severe, warns FDA
• Neuroleptics
  • Failure to Medicate Does Not Harm Patients
• Neuroleptics and Chronic Mental Illness.
• Alprazolam-Induced Panic Disorder
• Researchers in the UK find alarmingly high mortality with the SSRI anti-depressants (Prozac, Paxi., etc). 
• Research reviewed by Robert Whitaker since the Release of Mad in America.
• Recent Developments from a Mad World
• Commonly-Prescribed Antidepressants Are Extremely Dangerous for Some
• Warning About Antipsychotic Drug (Zyprexa)
• Grand Jury Investigation Demanded against Eli Lilly for fraudulently concealing dangerousness of Prozac.

• Researchers warn antipsychotic drug might be linked to diabetes

• Revised safety labeling for Accutane

• Psychiatric Risk Management–Accutane

• 2002 Safety Alert - Zoloft (sertraline hydrochloride)

• Glaxo Smith Kline internal confidential memo (1998) stating it is the company's policy to conceal evidence from regulators.

• ClinicalTrials.Gov is a database of clinical trials.

The FDA has a reporting system which the public and physicians are encouraged to use. 
https://www.accessdata.fda.gov/scripts/medwatch  and 
http://www.fda.gov/medwatch/getforms.htm

FAIR USE NOTICE: These links may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, this material is used for non-profit educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.  Any copyright owner who objects to the use of their copyrighted material should send an e-mail to webmaster@psychrights.org.

Last Modified 7/17/2017
Copyright © 2002-2010 Law Project For Psychiatric Rights  All Rights Reserved